The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 28, 2025

Filed:

Mar. 07, 2024
Applicant:

Vor Biopharma Inc., Cambridge, MA (US);

Inventors:

Anthony Boitano, Newton, MA (US);

Michael Cooke, Boston, MA (US);

Charlotte Fenton McDonagh, Winchester, MA (US);

Rahul Palchaudhuri, Somerville, MA (US);

Rajiv Panwar, Acton, MA (US);

Bradley R. Pearse, Watertown, MA (US);

Paul Fredrick Widboom, Hanover, NH (US);

Patricia Ann Cruite, Medford, MA (US);

Assignee:

Vor Biopharma, Inc., Cambridge, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); A61K 35/28 (2015.01); A61K 47/68 (2017.01); A61P 35/02 (2006.01); A61P 37/06 (2006.01); C07K 16/28 (2006.01); C12P 21/08 (2006.01); A61K 35/12 (2015.01); A61K 39/00 (2006.01); C07K 1/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/289 (2013.01); A61K 35/28 (2013.01); A61K 47/6803 (2017.08); A61K 47/68035 (2023.08); A61K 47/6849 (2017.08); A61P 35/02 (2018.01); A61P 37/06 (2018.01); A61K 2035/124 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01);
Abstract

Disclosed are anti-CD45 antibodies, antigen binding fragments thereof, and antibody drug conjugates (ADCs) that specifically bind to human CD45. Such antibodies and ADCs are useful in therapeutic methods, including methods of depleting CD45+ cells from a patient. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD45+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy, and to improve the engraftment of hematopoietic stem cell transplants, by selectively depleting endogenous CD45+ cells prior to the transplant procedure.


Find Patent Forward Citations

Loading…